Sign In
Buy NDAQ
$82.61
+0.370 (+0.450%)
At Close: Jun 22, 2026
SPACSphere Acquisition Corp. Announces the Pricing of $150,000,000 Initial Public Offering
05:21pm, Thursday, 05'th Feb 2026
GRAND CAYMAN, Cayman Islands, Feb. 05, 2026 (GLOBE NEWSWIRE) -- SPACSphere Acquisition Corp. (the “Company”) today announced the pricing of its initial public offering of 15,000,000 units at a pri
Nasdaq 2026 Investor Day
04:05pm, Thursday, 05'th Feb 2026
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Nasdaq will hold its 2026 Investor Day at the company's Global Headquarters in Times Square, New York. Due to limited capacity, in-person attendance is by i
Nasdaq Reports January 2026 Volumes
04:05pm, Wednesday, 04'th Feb 2026
NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today reported monthly volumes for January 2026 on its Investor Relations website. A data sheet showing this information can be found
Japan's Osaka Exchange Adopts Nasdaq Eqlipse Trading and Surveillance Technology for Next-Generation Derivatives Platform
02:18am, Wednesday, 04'th Feb 2026
OSE's technology modernization strengthens Japan's position as a leading global derivatives market Expands Nasdaq's comprehensive technology partnership across Japan's financial services ecosystem
Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement
04:05pm, Tuesday, 03'rd Feb 2026
Common Stock Will Begin Trading on Split-Adjusted Basis on February 6, 2026 Common Stock Will Begin Trading on Split-Adjusted Basis on February 6, 2026
Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol “PLYX”
08:30am, Monday, 02'nd Feb 2026
PARAMUS, NJ, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (“Polaryx” or the “Company”) a clinical-stage biotechnology company dedicated to the discovery, development, and commerciali
Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026
07:30am, Monday, 02'nd Feb 2026
CELEBRATION, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with
NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- K2 Capital Acquisition Corporation (the "Company") today announced the closing of its upsized initial public offering of 13,800,000 units at $10.00 per unit
Polaryx Therapeutics Announces Approval to List Common Stock on Nasdaq
08:00am, Friday, 30'th Jan 2026
PARAMUS, NJ, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (“Polaryx” or the “Company”) a clinical-stage biotechnology company dedicated to the discovery, development, and commerciali
Cold Feet Over AI Spending Brings Nasdaq Down
07:40pm, Thursday, 29'th Jan 2026
Microsoft (MSFT) the second-largest erasure of market-cap in one day's worth of trading: -$430 billion in one day.
Nasdaq, Inc. (NDAQ) Q4 2025 Earnings Call Transcript
12:12pm, Thursday, 29'th Jan 2026
Nasdaq, Inc. (NDAQ) Q4 2025 Earnings Call Transcript
Nasdaq Beats Q4 Earnings & Revenue Estimates, Tweaks Expense View
11:55am, Thursday, 29'th Jan 2026
NDAQ's fourth-quarter results reflect higher revenues across divisions and organic growth, partially offset by higher expenses.
Compared to Estimates, Nasdaq (NDAQ) Q4 Earnings: A Look at Key Metrics
10:31am, Thursday, 29'th Jan 2026
Although the revenue and EPS for Nasdaq (NDAQ) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Stree
Nasdaq CEO Adena Friedman on Q4 results: See a lot of momentum going into 2026
10:19am, Thursday, 29'th Jan 2026
Nasdaq CEO and Chair Adena Friedman joins 'Squawk Box' to discuss the company's quarterly earnings results, impact of AI, and more.
Nasdaq (NDAQ) Tops Q4 Earnings and Revenue Estimates
09:15am, Thursday, 29'th Jan 2026
Nasdaq (NDAQ) came out with quarterly earnings of $0.96 per share, beating the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $0.76 per share a year ago.
